Erenumab Efficacy in Treating Persistent Migraine and Remedy Overuse Headache

Persistent migraine (CM) is a debilitating situation that impacts tens of millions of people worldwide. A major subset of sufferers with CM additionally suffers from Remedy Overuse Headache (MOH), a secondary headache dysfunction brought on by the extreme use of acute headache drugs. Erenumab, a calcitonin gene-related peptide (CGRP) receptor antagonist, has been studied for its potential to induce MOH remission in sufferers with power migraine (1^✔ ✔Trusted Supply
Efficacy and Security of Erenumab for Nonopioid Remedy Overuse Headache in Persistent Migraine

Go to supply

).

Findings of Efficacy and Security of Erenumab in Persistent Migraine with Nonopioid Remedy Overuse Headache

The trial included 584 contributors within the nonopioid-treated cohort. The imply age of contributors was 44 years, with 82.5% of contributors being feminine (482 people). Baseline demographics and illness traits had been balanced throughout the examine teams.

Individuals had been randomly assigned to obtain month-to-month injections of both Erenumab 140 mg or Erenumab 70 mg or Placebo.

The first endpoint of the examine was the remission of MOH at month 6. Secondary endpoints included the discount in the usage of acute headache medicine days (AHMD) and the analysis of antagonistic occasions.

Efficacy in MOH Remission

The outcomes confirmed that erenumab was efficient in inducing MOH remission in sufferers with power migraine and nonopioid MOH:

• Erenumab, 140 mg group: 69.1% achieved MOH remission at month 6, with a statistically vital odds ratio (OR) of two.01 (95% CI, 1.33-3.05; P < .001) in comparison with placebo.
• Erenumab, 70 mg group: 60.3% achieved MOH remission, with an OR of 1.37 (95% CI, 0.92-2.05; P = .13) in comparison with placebo.
• Placebo group: 52.6% achieved MOH remission.

Though each doses of erenumab demonstrated efficacy, solely the 140 mg dose met the statistical significance threshold for MOH remission in comparison with placebo.

Discount in Acute Headache Remedy Days (AHMD)

Individuals within the erenumab teams confirmed a major discount in AHMD in comparison with placebo:

• Erenumab, 140 mg: The least squares imply discount in AHMD was –9.4 days (distinction from placebo, –2.7; 95% CI, –3.9 to –1.6; P < .001).
• Erenumab, 70 mg: The discount in AHMD was –7.8 days (distinction from placebo, –1.2; 95% CI, –2.4 to –0.1; P = .03).
• Placebo group: The discount in AHMD was –6.6 days.

Sustained MOH Remission

MOH remission was sustained all through the 6-month double-blind remedy interval (DBTP):

• Erenumab, 140 mg group: 61.3% sustained remission
• Erenumab, 70 mg group: 49.5% sustained remission
• Placebo group: 37.6% sustained remission

Security Profile

The security of erenumab was per earlier research. The incidence of treatment-emergent antagonistic occasions within the mixed erenumab group was 66.8%. The most typical antagonistic occasions had been:

• Constipation: 15.2%
• COVID-19 infections: 13.9%

No new security issues had been recognized throughout the trial.

The findings from this randomized medical trial show that month-to-month injections of 140 mg erenumab had been efficient in inducing MOH remission in sufferers with power migraine and nonopioid medicine overuse headache inside 6 months. The 70 mg dose confirmed some profit however didn’t meet the edge for statistical significance. Moreover, each doses of erenumab considerably lowered the usage of acute headache drugs, additional supporting its potential position in managing this difficult affected person inhabitants.

Commercial

These outcomes present sturdy proof for the usage of erenumab as a preventive remedy in sufferers with power migraine and medicine overuse complications, providing hope for higher administration of this burdensome situation.

Reference:

1. Efficacy and Security of Erenumab for Nonopioid Remedy Overuse Headache in Persistent Migraine – (https://jamanetwork.com/journals/jamaneurology/fullarticle/2823594?guestAccessKey=eaf63723-49d8-4ab9-b76b-b3c2d525b92d)

Supply-Medindia